Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifurtimox in Pediatric Chagas Disease (CHICO)
NCT02625974Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2016
- Primary completion
- Jul 2018
- Modality
- Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
A Phase 3 trial of nifurtimox in Chagas disease, sponsored by Bayer. Started Jan 2016; status: completed.
02
Drugs
nifurtimox
03
Conditions
Chagas disease
Beyond the preview
Go deeper on NCT02625974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02625974.